Two heart drugs fail at AHA meeting
Two experimental heart-disease drugs failed to reduce major cardiovascular events at the American Heart Association meeting. Novartis is largely abandoning an experimental heart drug, and Novo Nordisk halted two other trials.
IllustrationThe story so far
At the American Heart Association meeting, two experimental heart-disease drugs failed to reduce major cardiovascular events. Novo Nordisk's ziltivekimab lowered IL-6 but did not cut heart attacks, strokes, or deaths, leading Novo to halt two other trials. Pelacarsen sharply lowered Lp(a) and LDL but showed no benefit in people with existing cardiovascular disease over nearly five years, with more discontinuations from side effects.
Following the presentation of key study details at the American Heart Association meeting, Novartis is largely abandoning an experimental drug after a study found it had little promise for preventing heart attacks and cardiovascular deaths. The result dealt a blow to research targeting lipoprotein(a), a genetic risk factor for cardiovascular disease. Other drugmakers, including Amgen, Eli Lilly, and Silence Therapeutics, are also pursuing drugs for this condition.
Latest updates
2 updates · newest first- 9 NovNew development
Novartis abandons experimental heart drug after trial results
Novartis is largely abandoning an experimental drug after a study found it had little promise for preventing heart attacks and cardiovascular deaths. The decision follows the presentation of key study details at the American Heart Association meeting, dealing a blow to the field of research targeting lipoprotein(a), a genetic risk factor for cardiovascular disease. Other drugmakers including Amgen, Eli Lilly, and Silence Therapeutics are also pursuing drugs for this condition.
STAT ↗
- 7 NovNew development
Two heart-disease drugs fail to cut major events at AHA meeting
Two experimental heart-disease drugs failed to reduce major cardiovascular events at the American Heart Association meeting. Novo Nordisk's ziltivekimab lowered IL-6 but did not cut heart attacks, strokes or deaths, leading Novo to halt two other trials. Pelacarsen sharply lowered Lp(a) and LDL but showed no benefit in people with existing cardiovascular disease over nearly five years, with more discontinuations from side effects.
MedPage Today ↗
NPR ↗